FSD Pharma Inc. HUGE FSDDF said Monday it has obtained approval for its Class B subordinate shares to list on the Nasdaq Capital Market.
The company hasn’t provided a specific date for when the stock will begin trading on the Nasdaq.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
FSD Pharma is a specialty biotech pharmaceutical research and development company oriented toward creating a variety of synthetic compounds addressing the human endocannabinoid system to help treat various central nervous system illnesses and autoimmune disorders.
During the second quarter of 2019, FSD Pharma purchased Prismic Pharmaceuticals.
FSD Pharma shares were trading 18.1% higher at $5.35 at the time of publication Monday.
Related Links:
Cannabis Earnings Roundup: 4Front, WeedMD, FSD Pharma, 1933 Industries, True Leaf
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!